文献速递神经肿瘤

光动力疗法辅助手术治疗胶质母细胞瘤的临床获益:系统综述与荟萃分析

Clinical benefits of photodynamic therapy in glioblastoma: systematic review and meta-analysis.
PubMed 文献 · J Neurosurg · 2026-01-16

该系统综述与荟萃分析纳入8项回顾性对照研究共772例胶质母细胞瘤患者,评估光动力疗法(PDT)作为手术辅助治疗的安全性与疗效。结果显示PDT显著改善无进展生存期(HR 0.66,95%CI 0.50-0.86;p=0.003)和总生存期(HR 0.57,95%CI 0.46-0.70;p<0.001),1年生存率较对照组提高25%(95%CI 10%-40%,p=0.001),且并发症发生率与对照组相似(RR 1.28,95%CI 0.66-2.46;p=0.46)。

要点

  • PDT辅助手术可显著改善GBM患者PFS和OS,1年生存率提高25%。
  • PDT组与对照组并发症发生率无显著差异, transient脑水肿约见于十分之一治疗患者。
  • Talaporfin sodium与5-ALA两种光敏剂对OS的影响无显著差异(p=0.32)。

核心结论

  • PDT作为手术辅助治疗可显著改善GBM患者的肿瘤控制和生存,且不增加主要并发症。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus、Embase和Web of Science(2024年9月),遵循PRISMA指南,纳入比较PDT安全性与疗效的对照队列研究,采用随机效应模型分析,ROBINS-I工具评估非随机研究质量。

主要发现

  • 共纳入8项回顾性研究、772例GBM患者(PDT组281例,对照组491例)。
  • PDT显著改善PFS(HR 0.66,95%CI 0.50-0.86;p=0.003)和OS(HR 0.57,95%CI 0.46-0.70;p<0.001)。
  • 1年生存率较对照组提高25%(95%CI 10%-40%,p=0.001)。
  • Talaporfin sodium与5-ALA对OS的影响无显著差异(p=0.32)。
  • 并发症发生率两组相似(RR 1.28,95%CI 0.66-2.46;p=0.46), transient脑水肿约见于十分之一治疗患者。

关键数值与推荐

  • PDT组PFS的HR为0.66(95%CI 0.50-0.86;p=0.003)。
  • PDT组OS的HR为0.57(95%CI 0.46-0.70;p<0.001)。
  • 1年生存率提高25%(95%CI 10%-40%,p=0.001)。
  • 并发症RR为1.28(95%CI 0.66-2.46;p=0.46)。
  • Talaporfin sodium与5-ALA的OS比较p=0.32。

临床怎么用

  • PDT可作为GBM手术中的辅助治疗选项,以改善局部肿瘤控制和生存。
  • 治疗前应与患者讨论 transient脑水肿风险(约十分之一)。
  • 需进一步随机临床试验验证长期疗效并优化治疗方案。

局限性

  • 纳入研究均为回顾性研究,证据等级有限。
  • 需要进一步随机临床试验验证长期疗效和优化治疗协议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glioblastoma (GBM) is an aggressive brain tumor with a poor prognosis despite standard treatments. Emerging innovations, including photodynamic therapy (PDT), offer new hope by improving local tumor control and survival. The aim of this review was to systematically assess the clinical benefits of PDT as an adjunct to surgery for patients with GBM. METHODS: A systematic review was conducted in September 2024 using PubMed, Scopus, Embase, and Web of Science, following PRISMA guidelines. Comparative cohort studies evaluating the safety and efficacy of PDT in patients with GBM were included. Oncological outcomes were assessed by comparing progression-free survival (PFS), overall survival (OS), and the difference in 1-year survival rates between the PDT and control groups. Statistical analysis was performed using a random-effects model, while study quality was evaluated with the ROBINS-I tool for nonrandomized studies. RESULTS: This review included 8 retrospective studies involving 772 patients with GBM (281 in the PDT group and 491 in the control group). Talaporfin sodium (TS) was used in 5 studies, while 5-aminolevulinic acid (5-ALA) was used in 3 studies. The analysis showed that PDT significantly improved the PFS (hazard ratio [HR] 0.66, 95% CI 0.50-0.86; p = 0.003) and OS (HR 0.57, 95% CI 0.46-0.70; p < 0.001) rates, leading to a notable increase of 25% in the 1-year survival rate compared with controls (95% CI 10%-40%, p = 0.001). There was no significant difference between TS and 5-ALA regarding OS outcomes (p = 0.32). Additionally, complication rates were similar between PDT-treated patients and controls (RR 1.28, 95% CI 0.66-2.46; p = 0.46), with transient cerebral edema reported in approximately one-tenth of treated patients. CONCLUSIONS: PDT significantly improved tumor control and extended survival for patients with GBM without increasing major complications. These findings support PDT as a promising adjunctive treatment during surgery. However, further randomized clinical trials are needed to validate its long-term efficacy and to optimize treatment protocols.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Dabbagh Ohadi MA, Soleimani S, Kakoienejad MM, et al. Clinical benefits of photodynamic therapy in glioblastoma: systematic review and meta-analysis. J Neurosurg. 2026. PMID: 41569684. doi:10.3171/2025.8.JNS25763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。